WO2014087240A3 - Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis - Google Patents

Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis Download PDF

Info

Publication number
WO2014087240A3
WO2014087240A3 PCT/IB2013/003100 IB2013003100W WO2014087240A3 WO 2014087240 A3 WO2014087240 A3 WO 2014087240A3 IB 2013003100 W IB2013003100 W IB 2013003100W WO 2014087240 A3 WO2014087240 A3 WO 2014087240A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compositions
preventing
kits
methods
Prior art date
Application number
PCT/IB2013/003100
Other languages
French (fr)
Other versions
WO2014087240A2 (en
Inventor
Michael Bezuhly
Robert Liwski
Original Assignee
Dalhousie University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalhousie University filed Critical Dalhousie University
Publication of WO2014087240A2 publication Critical patent/WO2014087240A2/en
Publication of WO2014087240A3 publication Critical patent/WO2014087240A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions, kits and methods for preventing and treating cancer in a subject (e.g., human) by preventing, reducing or eliminating cancer (e.g., cancerous tumor) metastasis include administration of an anti-platelet agent that inhibits metastasis of cancer cells in a subject having cancer, and optionally, one or more additional anti-cancer agents. The compositions, methods and kits can be used for preventing and treating any cancer with metastatic potential such as, for example, metastatic melanoma and breast cancer. The compositions can be used as adjuvant therapy against cancer in combination with chemotherapy and/or radiation therapy (e.g., chronic or short term adjuvant therapy).
PCT/IB2013/003100 2012-12-04 2013-12-04 Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis WO2014087240A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261733363P 2012-12-04 2012-12-04
US61/733,363 2012-12-04
US201361798309P 2013-03-15 2013-03-15
US61/798,309 2013-03-15
US201361888579P 2013-10-09 2013-10-09
US61/888,579 2013-10-09

Publications (2)

Publication Number Publication Date
WO2014087240A2 WO2014087240A2 (en) 2014-06-12
WO2014087240A3 true WO2014087240A3 (en) 2014-10-23

Family

ID=50884091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/003100 WO2014087240A2 (en) 2012-12-04 2013-12-04 Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis

Country Status (1)

Country Link
WO (1) WO2014087240A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177473A1 (en) 2012-05-25 2013-11-28 The University Of Vermont And State Agriculture College Compositions and methods for assaying platelet reactivity and treatment selection
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
CN109646442B (en) * 2019-01-29 2023-01-24 军事科学院军事医学研究院生物医学分析中心 Application of acetate compound in preparation of cycloguanosine synthetase acetylation drugs
CN113677341A (en) * 2019-02-01 2021-11-19 南卡罗莱纳大学 Bicyclic pyridine compositions and methods of use for cancer treatment
AU2022323178A1 (en) * 2021-08-04 2024-02-15 University Of Vermont And State Agricultural College Methods for selecting a cancer patient for treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963559A (en) * 1978-01-06 1990-10-16 Sanofi Method of treating cancer and cancer metastasis
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963559A (en) * 1978-01-06 1990-10-16 Sanofi Method of treating cancer and cancer metastasis
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. HIROYASU ET AL.: "Effects of Antiplatelet Agents on Pulmonary Metastases", GANN, vol. 75, 1984, pages 284 - 291 *
C. LI ET AL.: "Apigenin Up-Regulates Transgelin and Inhibits Invasion and Migration of Colorectal Cancer through Decreased Phosphorylation of AKT", J. NUTRI. BIOCHEM., vol. 24, 2013, pages 1766 - 1775 *
K. MURATA ET AL.: "Phosphodiesterase Type III Inhibitor, Cilostazol, Inhibits Colon Cance Cell Motility", CLINICAL & EXPERIMENTAL METASTASIS, vol. 17, 1999, pages 525 - 530 *
P. M. ROTHWELL ET AL.: "Effect of Daily Aspirin on Risk of Cancer Metastasis: A Study Incident Cancers during Randomised Controlled Trials", LANCET, vol. 379, 2012, pages 1591 - 1601 *

Also Published As

Publication number Publication date
WO2014087240A2 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
CL2015003285A1 (en) Arylquinazolines
MA39906A (en) Combination therapies for the treatment of cancer
PH12016502066A1 (en) Methods of treating bladder cancer
WO2017216772A3 (en) Methods and compositions for treating breast and prostate cancer
MX2016006726A (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
MX2015011753A (en) Methods of treating bladder cancer.
EP3134115A4 (en) Methods and compositions for treating metastatic breast cancer and other cancers in the brain
EA201992251A1 (en) ANTI-CANCER VACCINES AND METHODS OF TREATMENT WITH THEIR APPLICATION
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX366804B (en) R-spondin translocations and methods using the same.
WO2016196741A3 (en) Low intensity focused ultrasound for treating cancer and metastasis
SG11201802915WA (en) Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
MX359210B (en) Procaspase 3 activation by combination therapy.
WO2014087240A3 (en) Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis
MX2015007185A (en) Use of eribulin in the treatment of breast cancer.
CL2015003595A1 (en) Cyp17 novel inhibitors / antiandrogens
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP3314250A4 (en) Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
MX2016008304A (en) Uses of oligouronates in cancer treatment.
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
WO2015089402A8 (en) Methods and compositions related to hsp90 inhibitors and breast cancer

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13860337

Country of ref document: EP

Kind code of ref document: A2